KrishnaRJuluriMDPhD

Hematologic Oncology

Director, Early Clinical Development at Bristol Myers Squibb

Dr. Juluri is on Doximity

As a Doximity member you'll join over two million verified healthcare professionals in a private, secure network.

Gain access to free telehealth tools, such as our “call shielding” and one-way patient texting.
Connect with colleagues in the same hospital or clinic.
Read the latest clinical news, personalized to your specialty.

University of WashingtonFellowship, Hematology and Medical Oncology, 2017 - 2021
Johns Hopkins University/Bayview Medical CenterResidency, Internal Medicine, 2015 - 2017
Johns Hopkins University School of MedicineClass of 2015

PubMed

13 citations
Asparaginase in the Treatment of Acute Lymphoblastic Leukemia in Adults: Current Evidence and Place in Therapy.
Krishna R Juluri, Chloe Siu, Ryan D Cassaday
Blood and Lymphatic Cancer. 2022-01-01
81 citations
Severe cytokine release syndrome is associated with hematologic toxicity following CD19 CAR T-cell therapy.
Krishna R. Juluri, Vicky Wu, Jenna M. Voutsinas, Jue Hou, Alexandre V. Hirayama
Blood Advances. 2021-10-19
3 citations
The tail of neuroendocrine tumors from lung to pancreas: Two rare case reports
Ashwin Soni, Epameinondas Dogeas, Krishna R. Juluri, Christopher L. Wolfgang, Ralph H. Hruban
International Journal of Surgery Case Reports. 2014-01-01

Lectures

Severe Cytokine Release Syndrome Is Associated with Impaired Hematopoietic Recovery after CD19-Targeted CAR-T Cell Therapy
61st Annual American Society of Hematology Meeting - Orlando, FL - 12/7/2019

Fred Hutch at ASH: Latest CAR T Data – BCMA, CD19, CD20 – plus New Insights on Transplantation, Gene Therapy – and MoreNovember 21st, 2019